LAURUSLABS.NS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 12:00):

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally...

Stats
Tagesvolumen	8.55M
Durchschnittsvolumen	2.20M
Marktkapitalisierung	235.50B
EPS	INR0 ( 2024-04-24 )
Nächstes Ertragsdatum	( INR0 ) 2024-07-25
Last Dividend	INR1.200 ( 2023-05-10 )
Next Dividend	INR0 ( N/A )
P/E	125.56
ATR14	INR0.883 (0.20%)

Volumen Korrelation

Lang: 0.20 (neutral)

Kurz: 0.41 (neutral)

Signal:(43.49) Neutral

Laurus Labs Limited Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Laurus Labs Limited Korrelation - Währung/Rohstoff

0.12
( neutral )

0.00
( neutral )

-0.02
( neutral )

0.29
( neutral )

0.27
( neutral )

-0.07
( neutral )

Laurus Labs Limited Finanzdaten

Annual	2023
Umsatz:	INR50.41B
Bruttogewinn:	INR15.84B (31.42 %)
EPS:	INR2.98

FY	2023
Umsatz:	INR50.41B
Bruttogewinn:	INR15.84B (31.42 %)
EPS:	INR2.98

FY	2022
Umsatz:	INR60.41B
Bruttogewinn:	INR32.66B (54.07 %)
EPS:	INR14.69

FY	2022
Umsatz:	INR48.89B
Bruttogewinn:	INR26.40B (54.01 %)
EPS:	INR15.42

Financial Reports:

No articles found.

Laurus Labs Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0.800 (N/A)	INR0 (N/A)	INR1.200 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Laurus Labs Limited Dividend Information - Dividend Knight

Dividend Sustainability Score: 8.01 - good (80.15%) | Divividend Growth Potential Score: 5.86 - Stable (17.17%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.300	2017-07-06
Last Dividend	INR1.200	2023-05-10
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	12	--
Total Paid Out	INR7.40	--
Avg. Dividend % Per Year	0.35%	--
Score	3.34	--
Div. Sustainability Score	8.01
Div.Growth Potential Score	5.86
Div. Directional Score	6.94	--

Next Divdend (Est)
(2024-05-13)

INR1.329 Estimate 3.60 %

Dividend Stability

0.29 Very Poor

Dividend Score

3.34

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2017	INR0	0.00%
2018	INR0.300	0.30%
2019	INR0.300	0.39%
2020	INR1.300	1.77%
2021	INR2.00	0.57%
2022	INR2.00	0.38%
2023	INR1.200	0.32%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SMLT.NS	Dividend Knight	2023-08-09	Semi-Annually	3	0.64%
MIDHANI.NS	Dividend Junior	2023-09-22	Semi-Annually	7	1.04%
HAVELLS.NS	Dividend Junior	2023-06-02	Annually	23	0.43%
BECTORFOOD.NS	Dividend Junior	2023-09-22	Semi-Annually	4	0.39%
PUNJABCHEM.NS	Dividend Junior	2023-07-27	Sporadic	18	0.16%
KENNAMET.NS	Dividend Knight	2023-05-25	Annually	4	0.76%
ELECTCAST.NS	Dividend Junior	2023-09-04	Annually	23	1.51%
AHLUCONT.NS	Dividend Junior	2023-09-22	Sporadic	15	0.04%
SUNPHARMA.NS	Dividend Junior	2023-07-28	Semi-Annually	29	0.77%
NAVA.NS	Dividend Knight	2023-07-24	Annually	23	2.35%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0318	1.500	9.36	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0191	1.200	9.36	10.00	[0 - 0.3]
returnOnEquityTTM	0.0396	1.500	-0.672	-1.007	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.232	0.800	8.84	7.07	[1 - 3]
quickRatioTTM	0.584	0.800	-1.272	-1.017	[0.8 - 2.5]
cashRatioTTM	0.0455	1.500	-0.858	-1.287	[0.2 - 2]
debtRatioTTM	0.300	-1.500	5.00	-7.50	[0 - 0.6]
interestCoverageTTM	2.19	1.000	-0.300	-0.300	[3 - 30]
operatingCashFlowPerShareTTM	10.62	2.00	6.46	10.00	[0 - 30]
freeCashFlowPerShareTTM	10.62	2.00	4.69	9.38	[0 - 20]
debtEquityRatioTTM	0.612	-1.500	7.55	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.465	1.000	5.58	5.58	[0.2 - 0.8]
operatingProfitMarginTTM	0.0795	1.000	-0.410	-0.410	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.227	1.000	9.85	9.85	[0.2 - 2]
assetTurnoverTTM	0.601	0.800	9.33	7.46	[0.5 - 2]
Total Score				8.01

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	146.63	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.0396	2.50	-0.432	-1.007	[0.1 - 1.5]
freeCashFlowPerShareTTM	10.62	2.00	6.46	9.38	[0 - 30]
dividendYielPercentageTTM	0.458	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.62	2.00	6.46	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.518	1.500	9.88	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.114	1.000	9.66	0	[0.1 - 0.5]
Total Score				5.86

Laurus Labs Limited

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.